Tetra Radar · FDA Approvals · Decision date

Quimilza: FDA decision date

Vanda Pharmaceuticals Inc (VNDA) · 12 December 2026

The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.

Source: 10-Q of 29 October 2026

The decision is pending.

Vanda Pharmaceuticals Inc on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.